Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM

Neurology

Volumn 84, Issue 7, 2015, Pages 710-719

  Suchorska, Bogdana ^a   Jansen, Nathalie L ^a   Linn, Jennifer ^a   Kretzschmar, Hans ^a   Janssen, Hendrik ^a   Eigenbrod, Sabina ^a   Simon, Matthias ^b   Pöpperl, Gabriele ^c   Kreth, Friedrich W ^a   La Fougere, Christian ^d   Weller, Michael ^e   Tonn, Joerg C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Katharinenhospital Stuttgart ^*  (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROETHYL LEVO TYROSINE F 18; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; (18F)FLUOROETHYLTYROSINE; ALKYLATING AGENT; DACARBAZINE; TYROSINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; GLIOBLASTOMA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODAL CHEMOTHERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STEREOTACTIC BIOPSY; TUMOR VOLUME; ADULT; AGED; ANALOGS AND DERIVATIVES; BRAIN; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MALE; MICROSURGERY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; LONGITUDINAL STUDIES; MALE; MICROSURGERY; MIDDLE AGED; NEUROSURGICAL PROCEDURES; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN; TYROSINE;

EID: 84923241771     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001262     Document Type: Article

References (24)

1. Koshy M, Villano JL, Dolecek TA, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 2012;107: 207-212.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
3. Li Y, Lupo JM, Parvataneni R, et al. Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. Neuro Oncol 2013;15:607-617.
4. Holodny AI, Makeyev S, Beattie BJ, Riad S, Blasberg RG. Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging. AJNR Am J Neuroradiol 2010;31:1042-1048.
5. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906-920.
6. Jansen NL, Graute V, Armbruster L, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 2012;39:1021-1029.
7. Galldiks N, Stoffels G, Ruge MI, et al. Role of O-(2-18Ffluoroethyl)- L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med 2013;54:2046-2054.
8. Gotz I, Grosu AL. [(18)F]FET-PET imaging for treatment and response monitoring of radiation therapy in malignant glioma patients: a review. Front Oncol 2013;3:104.
9. Piroth MD, Holy R, Pinkawa M, et al. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 2011;99:218-224.
10. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)- L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005; 128:678-687.
11. Mehrkens JH, Popperl G, Rachinger W, et al. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 2008;88:27-35.
12. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
13. Grasbon-Frodl EM, Kreth FW, Ruiter M, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007;121:2458-2464.
14. Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 2013;24:3117-3123.
15. Jansen NL, Suchorska B, Schwarz SB, et al. [18F]fluoroethyltyrosine- positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Mol Imaging 2013;12:137-147.
16. Galldiks N, Langen KJ, Holy R, et al. Assessment of treatment response in patients with glioblastoma using O-(2- 18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med 2012;53:1048-1057.
17. Piroth MD, Liebenstund S, Galldiks N, et al. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-18fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful? Mol Imaging 2013;12: 388-395.
18. Radbruch A, Fladt J, Kickingereder P, et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol 2015;17:151-159.
19. Popperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47:393-403.
20. Langen KJ, Hamacher K, Weckesser M, et al. O-(2-[18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006;33:287-294.
21. Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C. Correlation of F-18- fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol 2008; 88:205-210.
22. Wyss MT, Hofer S, Hefti M, et al. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med 2007;48:1047-1052.
23. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963-1972.
24. Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70:234-243; discussion 243-244.